All stock lists
Capricor Therapeutics, Inc. (NASDAQ:CAPR)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
11.22+2.35 (+26.49%)
Market cap
$650M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 13, 2007
Website
Insider Score
––Not scored
CAPR Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
CAPR analyst forecast
CAPR analyst consensus
Moderate Buy4 ratings
Buy 4 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
CAPR 12-month price target
$23.00+105.0% upsideaverage of 2 firms
$25.00High
$21.00Low
Best analysts covering CAPR
- Jones Trading100%success rate · +202.5% avg return · 1 call
- Oppenheimer100%success rate · +285.4% avg return · 1 call
- HC Wainwright & Co.89%success rate · +110.6% avg return · 18 calls
- Cantor Fitzgerald75%success rate · +92.3% avg return · 4 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
CAPR analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Jones Trading | Buy | — | — | Upgraded | 2026-11-11 |
| — | B. Riley Securities | Buy | — | — | Upgraded | 2026-09-14 |
| B.Riley Financial | — | $21.00 | +150.9% | — | 2026-09-14 | |
| Piper Sandler | Overweight | $25.00 | +152.3% | Upgraded | 2026-09-01 | |
| — | Cantor Fitzgerald | Overweight | — | — | Upgraded | 2026-08-14 |
| — | Jones Trading | Hold | — | — | Downgraded | 2026-07-31 |
| — | HC Wainwright & Co. | Neutral | — | — | Downgraded | 2026-07-30 |
| — | Piper Sandler | Neutral | — | — | Downgraded | 2026-07-30 |
| — | Cantor Fitzgerald | Neutral | — | — | Downgraded | 2026-07-30 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-05-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-13 |
| — | B. Riley Securities | Buy | — | — | Reiterated | 2026-03-13 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-03-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-10 |
| — | B. Riley Securities | Buy | — | — | Reiterated | 2025-12-15 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-12-10 |
| — | Oppenheimer | Outperform | — | — | Reiterated | 2025-12-08 |
| — | Maxim Group | Buy | — | — | Reiterated | 2025-12-04 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-12-03 |
CAPR earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-12 | -0.51 | -0.62 | $525K | $0 |
| 2026-05-12 | -0.55 | -0.59 | $40.0M | $0 |
| 2026-08-14 | -0.59 | -0.70 | $2.1M | $0 |
| 2026-11-10 | -0.44 | -0.73 | $15.3M | $0 |
| 2027-03-11Upcoming | 0.12 | — | $52.8M | — |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.